Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life
Though survival outcomes have improved dramatically over the last few decades in newly diagnosed myeloma patients, elderly patients have not yielded the same magnitude of benefit as evidenced by higher rates of reported myeloma-related deaths in patients over the age of 75. This is of particularly importance given this cohort comprises a large proportion of myeloma patients with the median age of diagnosis being 70 years. One contributor to this discrepancy is reduced utilization of high-dose therapy and autologous stem cell transplant (HDT/ASCT) in this population due to concerns for increased toxicity and safety.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Nisha S. Josepht, Vikas A. Gupta, Sarah Wyman, Michael Graiser, Jonathan L. Kaufman, Dhwani Almaula, Joel Andrews, Craig Hofmeister, Madhav Dhodapkar, Leonard T. Heffner, Sagar Lonial, Ajay K. Nooka Source Type: research
More News: Biology | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Toxicology | Transplants